Sunday, November 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 17, 2026

This Will Be McDonald’s Stock Price Next Year

View original at finance.yahoo.com
This Will Be McDonald’s Stock Price Next Year Quick Read McDonald’s (MCD) achieved Q4 2025 revenue of $7B (up 9.7% year-over-year) and EPS of $3.12, beating estimates, while its loyalty platform scaled to 210 million active users generating approximately $37B in annual sales and driving 6.8% U.S…
Opening lines of the source · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • McDonald's executed a V-shaped recovery through 2025, its loyalty platform is scaling rapidly, and valuation remains reasonable for a franchise-dominant, cash-generating business of this quality

    60% confidence
  • Loyalty program is approaching 250 million users

    60% confidence
  • McDonald's stock price target is $342, implying 9.7% upside over the next 12 months

    60% confidence
  • McDonald's plans 2,600 new restaurant openings globally in 2026 to drive 2.5% systemwide sales growth

    60% confidence
  • 24/7 Wall St. recommendation is buy with a 90% confidence level

    60% confidence
  • The risk-reward tilts constructively for patient investors based on comp sales acceleration, loyalty program scaling to $37 billion in annual sales, and continued restaurant expansion in 2026

    60% confidence

Data points we hold from this source

McDonald's Corporation · stock return ytd0.77 percent
McDonald's Corporation · stock return 1y0.28 percent
McDonald's Corporation · comparable sales growth global5.7 percent
McDonald's Corporation · eps3.12 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Conflicts between sources are checked by an editor before we publish them here.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,959
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,959 facts checked against source5,585 source documents archived
Query this data → isubstrate.com

Working data, not the finished story. This is what our AI has read and extracted from source documents so far. How we source

This Will Be McDonald’s Stock Price Next Year: Source | Via News | finance.via.news